The estimated Net Worth of David A Lemoine is at least $6.37 Million dollars as of 11 November 2021. Mr. Lemoine owns over 8,822 units of Insulet stock worth over $3,489,051 and over the last 14 years he sold PODD stock worth over $2,629,931. In addition, he makes $252,250 as Independent Director at Insulet.
Sign up
Mr. Lemoine PODD stock SEC Form 4 insiders trading
David has made over 20 trades of the Insulet stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 8,822 units of PODD stock worth $296,772 on 11 November 2021.
The largest trade he's ever made was selling 9,626 units of Insulet stock on 15 May 2019 worth over $1,025,362. On average, David trades about 1,377 units every 149 days since 2010. As of 11 November 2021 he still owns at least 15,321 units of Insulet stock.
You can see the complete history of Mr. Lemoine stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Lemoine biography
David A. Lemoine serves as Independent Director of the Company. Mr. Lemoine has served on our Board of Directors since February 2016. He has also served on the Board of Directors of The L.S. Starrett Company since 2010. From 1985 until his retirement in 2010, Mr. Lemoine held the position of Audit Partner at Deloitte & Touche LLP, a public accounting firm. From 1995 to 2000, he served as Deloitte’s Boston office Audit Partner-in-Charge. From 1985 to 1995, Mr. Lemoine served as Deloitte’s Managing Partner of their Worcester, Massachusetts location. From 1980 to 1985, he was Senior Vice President, Finance and Administration at a medical equipment manufacturer. Mr. Lemoine was a Lecturer at Boston College’s Carroll School of Management from 2008 to 2014, where he taught courses in Ethics and Accounting. He earned a Bachelor of Arts in Economics from Boston College and a Master of Science in Accounting from Northeastern University. He is a Certified Public Accountant and a member of the American Institute of Certified Public Accounts and the Massachusetts Society of CPAs. Mr. Lemoine has over 40 years of audit and finance experience and a deep knowledge of accounting, financial reporting and internal controls across a broad array of industries, including manufacturing, biotechnology, pharmaceutical, technology, and healthcare. Mr. Lemoine qualifies as an “audit committee financial expert” under the rules of the SEC.
What is the salary of David Lemoine?
As the Independent Director of Insulet, the total compensation of David Lemoine at Insulet is $252,250. There are 14 executives at Insulet getting paid more, with Shacey Petrovic having the highest compensation of $5,883,980.
How old is David Lemoine?
David Lemoine is 72, he's been the Independent Director of Insulet since 2016. There are no older and 21 younger executives at Insulet.
What's David Lemoine's mailing address?
David's mailing address filed with the SEC is C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON, MA, 01720.
Insiders trading at Insulet
Over the last 18 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman und Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.
What does Insulet do?
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
What does Insulet's logo look like?
Complete history of Mr. Lemoine stock trades at Insulet und L.S. Starrett Co
Insulet executives and stock owners
Insulet executives and other stock owners filed with the SEC include:
-
Shacey Petrovic,
President, Chief Executive Officer, Director -
Wayde McMillan,
Chief Financial Officer, Executive Vice President, Treasurer -
Charles Alpuche,
Chief Operating Officer, Executive Vice President -
Bret Christensen,
Executive Vice President and Chief Commercial Officer -
John Kapples,
Senior Vice President, General Counsel, Secretary -
Shacey Petrovic,
Pres, CEO & Director -
Michael Spears,
Senior Vice President - Regulatory Affairs and Compliance -
Charles Alpuche,
Exec. VP & COO -
Wayde D. McMillan,
Exec. VP,CFO & Treasurer -
Bret Christensen,
Exec. VP & Chief Commercial Officer -
Dan Manea,
Sr. VP & Chief HR Officer -
Corinne Nevinny,
Independent Director -
timothy Scannell,
Independent Chairman of the Board -
James Hollingshead,
Independent Director -
David Lemoine,
Independent Director -
Sally Crawford,
Independent Director -
Jessica Hopfield,
Independent Director -
Michael Minogue,
Independent Director -
John Fallon,
Independent Director -
Deborah Gordon,
Vice President - Investor Relations and Corporate Communications -
Wayne Frederick,
Director -
Eric Benjamin,
Senior Vice President, Innovation and Strategy -
John Wodick Kapples,
Sr. VP, Sec. & Gen. Counsel -
Michael Spears,
Sr. VP of Regulatory Affairs & Compliance -
Angela Geryak Wiczek,
Sr. Director of Corp. Communications -
Lauren Budden,
VP, Chief Accounting Officer & Controller -
David Colleran,
SVP, Secretary and GC -
Regina O Sommer,
Director -
Michael L Levitz,
CFO -
Bradley A Thomas,
EVP Human Resources -
Joseph S Zakrzewski,
Director -
Daniel J Levangie,
Director -
Luciana Borio,
Director -
James C Mullen,
Director -
John Garibotto,
Vice President of Research -
Luis Malave,
Chief Operating Officer -
Aiman Abdel Malek,
SVP, Advanced Technology -
Ruthann De Pietro,
Vice President of Quality -
Patrick J Sullivan,
President & CEO -
Ross A Md Jaffe,
Director -
Carsten Boess,
Chief Financial Officer -
David A Howe,
VP of Human Resources -
Jason Ng,
Vice President of Asian Operat -
W Mark Lortz,
Director -
Steven Sobieski,
Director -
William D Iii Arthur,
V.P. of Business Development -
Peter Devlin,
Chief Commercial Officer -
Brian K Roberts,
Chief Financial Officer -
Lars Boesgaard,
Vice President of Finance -
Shawna Gvazdauskas,
Vice President of Sales -
R Anthony Diehl,
General Counsel -
Gary Eichhorn,
Director -
Kevin Schmid,
Vice President Manufacturing -
John L Brooks,
10% owner -
Charles T Liamos,
Director -
Allison Dorval,
Chief Financial Officer -
Tracey Haas Wielinski,
VP, Global Regulatory, CA, QA -
William Patrick Ryan,
Chief Operating Officer -
Duane De Sisto,
President and CEO -
Advisors Llc Orbimed,
Director -
Andrew Suchoff,
Chief Human Resources Officer -
Venture Capital I Lpversant...,
-
Venture Partners Iii Llc Prism,
10% owner -
Jonathan Silverstein,
Director -
Venture Partners Iii A Lp P...,
10% owner -
Venture Partners Iii Lp Prism,
10% owner -
Venture Partners Iii A Lp P...,
-
De Bord Alison Peyromaure,
Director -
Capital Management Inc Pequot,
-
Investment Partners Iii Lp ...,
10% owner -
Stephen Bubrick,
Vice President of Customer -
William M Seifert,
10% owner -
Gordon E Nye,
10% owner -
Samuel D Colella,
-
Jefferey Smith,
Vice President of Marketing -
Robert Campbell,
Vice President for Clinical -
Dan Manea,
SVP, Chief HR Officer -
Prem Singh,
SVP, Global Operations -
Timothy C. Stonesifer,
Director -
Flavia Pease,
Director -
Elizabeth H Weatherman,
Director -
Lauren Budden,
Group VP, CAO and Controller -
Laetitia Cousin,
SVP, Reg, Quality & Compliance -
Mark N Field,
SVP & Chief Technology Officer -
Ana Maria Chadwick,
EVP, CFO & Treasurer